HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VMS Market Regulation Gets Targeted Funding In US FDA Budget; OTC Switches Get Question

Executive Summary

In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.

You may also be interested in...



US Hemp Product Industry ‘Dying On Vine’ Without Lawful Use Legislation Or Enforcement Guidance

FDA’s tolerance of sales of hemp-containing supplements isn’t the assurance  industry needs for investing in development of ingredients and products which have been shown to provide various health benefits.

US Cannabis Legalization Cultivated By House Has Thorny Forecast For Harvest In Senate

Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.

COVID-19 Claim Warnings To US CBD Firms? Yes; References To Unlawful Use Of Hemp? No

Seven of nine firms targeted in US regulators’ recent warning letters about unlawful COVID-19 claims are offering supplements containing hemp ingredients. Former naturopathic physician sentenced to prison and probation for conviction on charges linked to offering bogus COVID-19 treatments.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel